🔗 Share this article

As the United States undertakes unprecedented changes to its vaccination recommendations, an unexpected name has emerged in a surprising turn: Høeg, a Danish American sports medicine doctor and epidemiologist who first made her name by expressing skepticism about COVID-19 vaccines throughout the pandemic and has focused upon possible fatalities after Covid immunization in her brief tenure at the FDA.

Proposed Shifts to Childhood Vaccine Schedule

Agency leaders had intended to announce radical changes to the childhood immunization program earlier this month, synchronizing the US with Denmark’s immunization schedule, it is understood – a significant shift that would place the US at odds with much of the global community with little proof for benefit. This reveal has been delayed until the new year.

Instead of the director of the vaccine center, Dr. Høeg is set to present at the gathering. She was recently named temporary leader of the FDA’s CDER, the fifth person to run the office this year.

Consolidating Power at the Regulatory Body

The acting appointment might represent a strengthened alliance between the pharmaceutical and vaccine branches as Høeg and Prasad consolidate power at the regulatory agency – and it points to a increased emphasis upon dismantling already-approved immunizations at the FDA.

The new acting director has frequently advocated for discontinuing certain pediatric immunization guidelines in the US so as to align more like the Danish model, a country with comprehensive healthcare and a citizenry roughly the population of the state of Wisconsin.

To date public appearances, she has persisted in emphasizing on vaccines – usually the purview of Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to pharmaceutical oversight.

Concerns Over Expertise

Dr. Høeg has no apparent background in drug development, oversight or leadership, which has been typical for former heads of the CBER. She has been employed at the FDA as a key advisor to the commissioner and the vaccine center since earlier this year.

“She doesn’t seem to have any of the qualifications” for overseeing the drug-regulation department, stated Jonathan Howard. “She’s never run a scientific study. She is not versed in managing a sizeable institution. She lacks background in drug approvals.”

Previous directors of CBER would “grasp legal statutes and the research of pharmaceutical innovation”, said Janet Woodcock. “Frankly, she lacks the type of experience that prior appointees who led CBER have had.”

This division has an enormous range of responsibilities at the agency, Woodcock pointed out.

“The public just focuses on the novel medication approvals, but the generic program approves numerous off-brand pharmaceuticals. There is also a biosimilars division, OTC medication office and more, and each of these must be managed,” Woodcock explained. “The responsibility you neglect, that is the part that I always told people is going to cause problems.”

Furthermore, a substantial administrative aspect to the job, which supervises more than 5,000 personnel. “It’s a huge administrative position, if you do it right,” the former official concluded.

Agency Reaction and Disputed Programs

In response to concerns about Høeg’s credentials and whether this assignment indicates greater collaboration among regulatory chiefs on immunizations, a representative responded that the “questions stem from flawed premises”.

“Her experience matches the functions of her role,” the representative said, citing the months Høeg spent guiding the agency head on “pharmaceutical safety and regulatory science, including computerized risk analysis and vaccine surveillance”.

As the temporary head, Høeg takes over the agency head's new fast-track approval initiative, a controversial expedited therapy clearance system that apparently troubled her preceding directors. “By what process are these medications being picked for this expedited pathway? Who makes the calls?” Dr. Howard questioned. “There’s a lot of secrecy occurring at the FDA right now.”

Broadly speaking, he stated, “the agency seems to be moving towards less stringent oversight of all drugs, aside from shots.”

Documented Track Record on Immunizations

Regarding immunizations, Høeg has a clearer, if problematic, past, some experts observe. She authored a analysis using unconfirmed volunteer-provided data to determine the incidence of myocarditis following COVID-19 immunization. She counseled the state of Florida chief medical officer Dr. Joseph Ladapo, who was said to have changed statistics to imply Covid vaccines are pose a greater threat than they are.

Among her “policy goals” for the current administration featured changing rules for recently developed shots and ending “non-essential” vaccines, she remarked after the election on a audio program. At the agency, Dr. Høeg has reportedly floated the idea of excluding adolescent males from obtaining COVID-19 vaccinations.

“She’s an all-around ideologue who starts off with her conclusions and tailors the evidence to fit the data in a very deceptive, fraudulent fashion,” Dr. Howard argued.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg became part of other contrarians, {like|